153 related articles for article (PubMed ID: 33451139)
1. The Interplay between HGF/c-met Axis and Nox4 in BRAF Mutated Melanoma.
Beretti F; Farnetani F; Reggiani Bonetti L; Fabbiani L; Zavatti M; Maiorana A; Pellacani G; Maraldi T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451139
[TBL] [Abstract][Full Text] [Related]
2. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
3. Association of activated c-Met with NRAS-mutated human melanomas.
Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
[TBL] [Abstract][Full Text] [Related]
4. Activated Hgf-Met Signaling Cooperates with Oncogenic BRAF to Drive Primary Cutaneous Melanomas and Angiotropic Lung Metastases in Mice.
Braun AD; Mengoni M; Bonifatius S; Tüting T; Gaffal E
J Invest Dermatol; 2020 Jul; 140(7):1410-1417.e2. PubMed ID: 31972251
[TBL] [Abstract][Full Text] [Related]
5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
6. Cold atmospheric plasma and silymarin nanoemulsion synergistically inhibits human melanoma tumorigenesis via targeting HGF/c-MET downstream pathway.
Adhikari M; Kaushik N; Ghimire B; Adhikari B; Baboota S; Al-Khedhairy AA; Wahab R; Lee SJ; Kaushik NK; Choi EH
Cell Commun Signal; 2019 May; 17(1):52. PubMed ID: 31126298
[TBL] [Abstract][Full Text] [Related]
7. The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
Filitis DC; Rauh J; Mahalingam M
Melanoma Res; 2015 Dec; 25(6):470-8. PubMed ID: 26317169
[TBL] [Abstract][Full Text] [Related]
8. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
Jubb AM; Ribas A; Sosman JA; McArthur GA; Yan Y; Rost S; Zhao S; Koeppen H
Histopathology; 2013 Sep; 63(3):351-61. PubMed ID: 23802768
[TBL] [Abstract][Full Text] [Related]
9. The Role of MET in Melanoma and Melanocytic Lesions.
Zhou Y; Song KY; Giubellino A
Am J Pathol; 2019 Nov; 189(11):2138-2148. PubMed ID: 31476283
[TBL] [Abstract][Full Text] [Related]
10. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
11. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
12. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.
Demkova L; Kucerova L
Mol Cancer; 2018 Feb; 17(1):26. PubMed ID: 29455657
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
14. Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes.
Clavijo-Cornejo D; Enriquez-Cortina C; López-Reyes A; Domínguez-Pérez M; Nuño N; Domínguez-Meraz M; Bucio L; Souza V; Factor VM; Thorgeirsson SS; Gutiérrez-Ruiz MC; Gómez-Quiroz LE
Biochimie; 2013 Jun; 95(6):1177-84. PubMed ID: 23333744
[TBL] [Abstract][Full Text] [Related]
15. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
16. HGF facilitates methylation of MEG3, potentially implicated in vemurafenib resistance in melanoma.
Jia X; Feng H; He S; Chen X; Feng H; Chen M; Hu X
J Gene Med; 2024 Jan; 26(1):e3644. PubMed ID: 38072402
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
18. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA
Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138
[TBL] [Abstract][Full Text] [Related]
20. HGF/c-MET Signaling in Melanocytes and Melanoma.
Czyz M
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
